Bispecific antibodies for MM

During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Hermann Einsele, University of Würzburg, Würzburg, DE, spoke to the MM Hub about bispecific antibodies for MM.

Generally, there are very few T cells that are functional against tumor cells. Bispecific T-cell engager (BiTE) technology provides a strategy to link functionally active T cells to tumor cells. Hermann Einsele talks about the 'immunological synapse' and the redirection of T cells to instate immune-mediated tumor destruction. The advantages and disadvantages of BiTEs, and the trials underway to refine treatment regimens, are also discussed.